美国 · SEC FORM 4
Edgewise Therapeutics, Inc.
EWTX · Nasdaq · CIK 0001710072 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
38 同一窗口内观察到的 Form 4 交易行
23 sales · 15 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-11-11 · Fox Jonathan C · $199.4K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Donovan Joanne M.CMO
▼○▼○▼▼
Russell Alan JChief Scientific Officer
○▼○▼
MOORE JOHN RGeneral Counsel
○▼
KOCH KEVINPresident and CEO
○▼
Derakhshan BehradChief Business Officer
○▼
Fox Jonathan CDirector
○○
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-11-11 · Fox Jonathan C.
近期 Form 4 活动
1买入
33卖出
25其他 Form 4 交易行
17SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出23 sale line(s) · 仅供背景
其他15 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 11,224,347
- 上期报告
- 9,543,843
- 日均成交量
- 2,003,524
- 回补天数
- 5.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-11-11 | Fox Jonathan C | 买入 (P) | Common Stock | 10,700 | USD 18.64 | USD 199,448 | SEC 申报 ↗ |
| 2025-04-03 | Thompson Peter A. | 买入 (P) | Common Stock | 496,771 | USD 20.13 | USD 10,000,000 | SEC 申报 ↗ |
| 2025-04-03 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 496,771 | USD 20.13 | USD 10,000,000 | SEC 申报 ↗ |
| 2024-01-23 | Thompson Peter A. | 买入 (P) | Common Stock | 454,545 | USD 11.00 | USD 4,999,995 | SEC 申报 ↗ |
| 2024-01-23 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 454,545 | USD 11.00 | USD 4,999,995 | SEC 申报 ↗ |
| 2023-12-26 | Fox Jonathan C | 买入 (P) | Common Stock | 10,857 | USD 9.30 | USD 100,970 | SEC 申报 ↗ |
| 2022-09-16 | Thompson Peter A. | 买入 (P) | Common Stock | 484,496 | USD 10.32 | USD 4,999,999 | SEC 申报 ↗ |
| 2022-09-16 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 484,496 | USD 10.32 | USD 4,999,999 | SEC 申报 ↗ |
| 2022-09-14 | Novo Holdings A/S | 买入 (P) | COMMON STOCK | 484,496 | USD 10.32 | USD 4,999,999 | SEC 申报 ↗ |
| 2022-05-18 | Thompson Peter A. | 买入 (P) | Common Stock | 138,000 | USD 7.21 | USD 994,980 | SEC 申报 ↗ |
| 2022-05-18 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 138,000 | USD 7.21 | USD 994,980 | SEC 申报 ↗ |
| 2021-03-30 | Thompson Peter A. | 买入 (P) | Common Stock | 359,375 | USD 16.00 | USD 5,750,000 | SEC 申报 ↗ |
| 2021-03-30 | ROOT JONATHAN D | 买入 (P) | Common Stock | 15,625 | USD 16.00 | USD 250,000 | SEC 申报 ↗ |
| 2021-03-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 359,375 | USD 16.00 | USD 5,750,000 | SEC 申报 ↗ |
| 2021-03-30 | Novo Holdings A/S | 买入 (P) | COMMON STOCK | 625,000 | USD 16.00 | USD 10,000,000 | SEC 申报 ↗ |
Form 4 申报证据
59 transaction lines in the latest 365-day window; 281 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Fox Jonathan C | 奖励／授予 (A) | Common Stock | 308 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-13 | Donovan Joanne M. | 卖出 (S) | Common Stock | 2,919 | USD 43.41 | USD 126,714 | SEC 申报 ↗ |
| 2026-08-12 | Russell Alan J | 卖出 (S) | Common Stock | 5,901 | USD 43.73 | USD 258,060 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Fox Jonathan C | 奖励／授予 (A) | Common Stock | 308 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-13 | Donovan Joanne M. | 卖出 (S) | Common Stock | 2,919 | USD 43.41 | USD 126,714 | SEC 申报 ↗ |
| 2026-08-12 | Russell Alan J | 卖出 (S) | Common Stock | 5,901 | USD 43.73 | USD 258,060 | SEC 申报 ↗ |
| 2026-08-12 | Russell Alan J | 期权行权／转换 (M) | Common Stock | 12,812 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-12 | MOORE JOHN R | 卖出 (S) | Common Stock | 5,016 | USD 43.83 | USD 219,830 | SEC 申报 ↗ |
| 2026-08-12 | MOORE JOHN R | 期权行权／转换 (M) | Common Stock | 12,499 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-12 | KOCH KEVIN | 卖出 (S) | Common Stock | 17,971 | USD 43.68 | USD 785,050 | SEC 申报 ↗ |
| 2026-08-12 | KOCH KEVIN | 期权行权／转换 (M) | Common Stock | 39,844 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-12 | Donovan Joanne M. | 卖出 (S) | Common Stock | 6,522 | USD 43.85 | USD 285,998 | SEC 申报 ↗ |
| 2026-08-12 | Donovan Joanne M. | 期权行权／转换 (M) | Common Stock | 12,812 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-12 | Derakhshan Behrad | 卖出 (S) | Common Stock | 5,100 | USD 43.81 | USD 223,420 | SEC 申报 ↗ |
| 2026-08-12 | Derakhshan Behrad | 期权行权／转换 (M) | Common Stock | 13,281 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-01 | Russell Alan J | 卖出 (S) | Common Stock | 200,000 | USD 39.41 | USD 7,882,000 | SEC 申报 ↗ |
| 2026-07-01 | Russell Alan J | 期权行权／转换 (M) | Common Stock | 200,000 | USD 0.36 | USD 71,195 | SEC 申报 ↗ |
| 2026-07-01 | Fox Jonathan C | 奖励／授予 (A) | Common Stock | 319 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-05 | Donovan Joanne M. | 卖出 (S) | Common Stock | 50,000 | USD 38.57 | USD 1,928,500 | SEC 申报 ↗ |
| 2026-05-05 | Donovan Joanne M. | 期权行权／转换 (M) | Common Stock | 50,000 | USD 7.08 | USD 354,000 | SEC 申报 ↗ |
| 2026-05-04 | Donovan Joanne M. | 卖出 (S) | Common Stock | 5,230 | USD 31.29 | USD 163,647 | SEC 申报 ↗ |
| 2026-04-01 | Fox Jonathan C | 奖励／授予 (A) | Common Stock | 339 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-01 | Donovan Joanne M. | 卖出 (S) | Common Stock | 28,662 | USD 32.31 | USD 926,069 | SEC 申报 ↗ |
| 2026-04-01 | Donovan Joanne M. | 期权行权／转换 (M) | Common Stock | 28,662 | USD 7.08 | USD 202,927 | SEC 申报 ↗ |
| 2026-03-31 | Donovan Joanne M. | 卖出 (S) | Common Stock | 21,338 | USD 32.12 | USD 685,377 | SEC 申报 ↗ |
| 2026-03-31 | Donovan Joanne M. | 期权行权／转换 (M) | Common Stock | 21,338 | USD 7.08 | USD 151,073 | SEC 申报 ↗ |
| 2026-03-27 | Donovan Joanne M. | 卖出 (S) | Common Stock | 16,358 | USD 30.98 | USD 506,771 | SEC 申报 ↗ |
| 2026-01-21 | Edris Badreddin | 卖出 (S) | Common Stock | 115,471 | USD 29.44 | USD 3,399,466 | SEC 申报 ↗ |
| 2026-01-21 | Edris Badreddin | 期权行权／转换 (M) | Common Stock | 115,471 | USD 1.47 | USD 170,264 | SEC 申报 ↗ |
| 2026-01-02 | Fox Jonathan C | 奖励／授予 (A) | Common Stock | 473 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-12 | Russell Alan J | 卖出 (S) | Common Stock | 100,000 | USD 21.12 | USD 2,112,000 | SEC 申报 ↗ |
| 2025-11-12 | Russell Alan J | 期权行权／转换 (M) | Common Stock | 100,000 | USD 0.18 | USD 18,000 | SEC 申报 ↗ |
| 2025-11-11 | Fox Jonathan C | 买入 (P) | Common Stock | 10,700 | USD 18.64 | USD 199,448 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | EWTX |
| CIK | 0001710072 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 281 transaction lines from 2021-03-30 to 2026-10-01 20 P purchase lines · 145 S sale lines · 116 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.